Earnings ·
NeuroPace reported second quarter 2026 financial results with total revenue of $22.8 million, a 17% increase from the…
NPCENeuroPace Inc
NeuroPace reported second quarter 2026 financial results with total revenue of $22.8 million, a 17% increase from the prior year period. RNS System revenue reached $22.5 million, reflecting 21.3% growth. The company posted a GAAP net loss of $6.2 million and an adjusted EBITDA loss of $2.8 million, both improvements over the previous year's figures. Management raised full-year 2026 total revenue guidance to between $99.5 million and $101.5 million, citing expected service revenue growth and sustained core business momentum. The company also launched its ECoG Assistant AI tool and reported positive clinical data from the NAUTILUS trial for idiopathic generalized epilepsy. NeuroPace operates in the medical device industry, specializing in brain-responsive neurostimulation systems for treating drug-resistant epilepsy.